iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Sun Pharma recalls 34,000 bottles of its generic high blood pressure medicine, in US

13 Feb 2023 , 03:37 PM

Sun Pharma Industries Limited informed that it is recalling more than 34,000 bottles of generic medication in the US market due to failed dissolution testing. This medicine is used to treat high blood pressure. 

According to the US Food and Drug Administration's Enforcement Report, Sun Pharmaceutical Industries' US-based arm is recalling large quantities of Diltiazem Hydrochloride extended-release capsules, which are used to treat angina, some types of irregular heartbeats, and high blood pressure.

The pharmaceutical company located in New Jersey has taken the decision to recall a specific batch of their product due to a failure in impurity control (Deacetyl Diltiazem Hydrochloride) during stability tests, as well as subpar results in dissolution testing as determined by the USFDA’s laboratory.

The lot was manufactured at the Mumbai-based drugmaker's Halol-based manufacturing facility in Gujarat. The affected lot was later supplied in the market by the company's US-based subsidiary.

On January 13, this year, the company began the Class II nationwide recall (US).

The USFDA explains that a Class II recall is called into action when a product that violates their standards may result in health problems that can be fixed with medical intervention, or when the likelihood of severe health consequences is low.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Sun Pharma
  • Sun Pharma news
  • Sun Pharma recall
  • Sun Pharma Updates
  • Sun Pharma USFDA
  • USFDA approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.